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1. INTRODUCTION 
High affinity binding sites for [3H]imipramine 
have been identified and pharmacologically 
characterized in brain and platelet membranes 
[l-4]. Several ines of evidence have suggested that 
this site is structurally related to the uptake site for 
serotonin and that high affinity [3H]imipramine 
binding can serve as a label of the serotonin 
transporter [4-71. In order to determine the 
molecular properties of the high affinity [3H]im- 
ipramine binding site and further characterize its 
structural relationship to the serotonin transporter, 
we initiated a series of experiments to solubilize 
and subsequently purify the binding site from 
human platelet membranes. The present report 
describes the solubilization of the [3H]imipramine 
binding site from human platelets. The solubilized 
binding site has a pharmacological profile and ca- 
tion requirement which is identical to the 
membrane-bound binding site. Optimal solubiliza- 
tion was achieved using the detergent 3-[(3-chol- 
amidopropyl)dimethylammonio] - 1-propanesulfo- 
nate (CHAPS) which is a zwitterionic derivative of 
cholic acid that has been successfully used for 
solubilization of other receptors [8, lo]. Partial 
purification of the solubilized [3H]imipramine bin- 
ding site was carried out by gel filtration chromato- 
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mphy using 2-nitro[3H]imipramine as a 
radioligand. 2-Nitro[3H]imipramine is one of 
several derivatives of imipramine synthesized in 
our laboratory [l 11, that has both a high affinity 
for the t3H]imipramine binding site and dissociates 
very slowly when incubations are done at 0-4°C 
[7,11,12]. 
2. MATERIALS AND METHODS 
2.1. Preparation of platelets 
Blood was collected from medication-free 
volunteers by venipuncture and gently mixed with 
an anticoagulent solution containing 16 mM citrate 
buffer and 1 mM EDTA. Platelets were isolated 
and platelet membranes were prepared as in [4,12]. 
2.2. Solubilization 
Platelet membranes were disrupted using a 
Brinkman polytron (setting 7, 20 s) in 50mM 
Tris-HCl (pH 7.4) containing 120 mM NaCl, 
5 mM KC1 (buffer A) and centrifuged at 15000 x g 
for 10min. The membrane fragments were 
suspended to 1Omg protein/ml in the above buffer 
containing 0.5% (w/v) CHAPS. The mixture was 
homogenized with a glass homogenizer using a 
glass pestle (5 strokes) and the homogenate was 
kept for 30 min on ice (0-4°C) and then centrifug- 
ed at 100000 x g for 60min. The resulting superna- 
tant was used for the assay of solubilized im- 
ipramine binding sites. In other experiments labell- 
ing of the imipramine binding site with 
2-nitro[3H]imipramine prior to solubilization was 
carried out. Disrupted platelet membranes (1.5 mg 
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protein/ml) were incubated with 4nM 
2-nitro[3H]imipramine (spec. act. 73.6 Ci/mmol, 
NEN, Boston MA) in buffer A with or without 
10pM imipramine at 22°C for 30min. Following 
incubation, membranes were centrifuged at 
20000 x g for 15 min and the supernatant contain- 
ing unbound 2-nitro[3H]imipramine was discard- 
ed. The pellet was solubilized as above. 
2.3. [3H]Irnipramine binding 
To determine [3H]imipramine binding to the 
solubilized membrane preparation the incubation 
mixture contained 100~1 solubilized membranes, 
100~1 [3H]imipramine (spec. act. 29.8 Ci/mmol, 
NEN, Boston MA) at final cont. 2nM (unless 
otherwise stated), 750~1 buffer A and 50~1 of the 
same buffer with or without chlorimipramine 
(500 nM). Chlorimipramine (500 nM) was added to 
determine non-specific binding. After incubation 
at 0°C for 60min, 100,J 10% (w/v) activated char- 
coal in buffer A containing 2% (w/v) bovine serum 
albumin was added and the mixture rapidly mixed. 
The samples were then maintained for 5 min on ice 
and subsequently centrifuged at 1500 x g for 
10min. An aliquot (800~1) of the supernatant was 
counted for radioactivity using a liquid scintilla- 
tion counter. Separation of protein, bound from 
free 2-nitro[3H]imipramine, is efficiently carried 
out using this procedure (unpublished). 
2.4. Gel filtration chromatography 
Sepharose CL-6B was equilibrated with buffer A 
containing 0.05% (w/v) CHAPS and packed in a 
53 x 1.7 cm glass chromatography column. A 2 ml 
sample of the soluble fraction obtained, following 
preincubation of platelet membranes with 
2-nitro[3H]imipramine, was applied to the column. 
The column was eluted in buffer A containing 
0.05% CHAPS at 4°C and at a flow-rate of 
0.15 ml/min. Fractions (1 ml) were collected using 
an automatic fraction collector and samples 
(100~1) from each fraction were counted for 
radioactivity in a liquid scintillation counter as in 
[7,111. 
3. RESULTS 
The binding of [‘Hlimipramine to the solubilized 
platelet membranes is saturable and of high affini- 
ty (fig. 1). In contrast, non-specific binding in- 
Fig. 1. Scatchard analysis of [3H]imipramine binding to 
CHAPS-solubilized platelets. Binding of various con- 
centrations of ligand was carried out at 0°C for 60min; 
non-specific binding was measured in the presence of 
5OOnM chlorimipramine. Bound [3H]imipramine was 
separated from free 13H)imipramine using the charcoal 
method as described in the text. Inset: saturation 
isotherm of specific [3H]imipramine binding. Values are 
from a representative xp. repeated 3-times with iden- 
tical results. 
creased linearly with increasing concentrations of 
[3H]imipramine (not shown). At 2 nM, the specific 
binding of [3H]imipramine was 60% of the total 
binding. Scatchard analysis indicated a single 
population of binding sites with an apparent 
dissociation constant (Kd) of 1.2nM and maximal 
number of binding sites (II,,& of 175 fmol/mg 
protein. The apparent & value of [3H]imipramine 
binding to solubilized membranes (1.2 nM) is iden- 
tical to the value obtained in intact platelet mem- 
branes (1.2 nM) [4], whereas the B,,, value observ- 
ed in the solubilized fraction was 30% of the value 
obtained in platelet membranes [4]. Specific 
[3H]imipramine binding to the soluble fraction was 
heat-sensitive, since preheating the solubilized bin- 
ding site to 50°C for 15 min prior to assay reduced 
specific binding by > 90%. 
[3H]Imipramine binding to the solubilized frac- 
tion was also found to be sensitive to trypsin. Pre- 
incubation of the solubilized membrane fraction 
with trypsin (1 mg/ml) for 30min at 25°C resulted 
in a 60% decrease of specific binding. Specific bin- 
ding was also found to be sodium-dependent, since 
increasing the [Na+] from lo-320 mM resulted in 
a highly significant increase (fig. 2) in specific 
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Fig. 2. Na+ dependency of [3H]imipramine binding to 
CHAPS-solubilized platelets. Specific binding was 
measured in the presence of various concentrations of 
sodium using 2nM [3H]imipramine and 500nM chlori- 
mipramine for measuring non-specific binding. The 
potassium ion concentration was kept constant (5 mM). 
Points represent the means of 2 exp. each done in 
triplicate. 
Specific [3H]imipramine binding to solubilized and 
membrane-bound binding sites [4] was carried out as 
described (text, [6,7]). ZCso values, representing the con- 
centration of unlabelled drug which inhibited 50% of the 
specific binding of [3H]imipramine (2nM), were 
calculated from displacement curves using 6 concentra- 
tions of unlabelled drug. Values represent he mean of 3 
[3H]imipramine binding. These results are identical 
to those observed using intact membranes, and 
represent an increase in the apparent affinity 
(decreased &) of [3H]imipramine in the presence 
of sodium (unpulished). 
separate xp. with SEM < 20% 
To characterize the pharmacological profile of 
the solubilized binding site, a series of antidepres- 
sants and other drugs were studied for their poten- 
cy in inhibiting [3H]imipramine binding to the 
soluble fraction. Table 1 shows the Z&-values for 
10 drugs in inhibiting the binding of t3H]imipra- 
mine (2nM) to the solubilized binding site. The 
relative potencies of these drugs are very similar to 
that obtained (table 1) using intact platelet mem- 
branes [4]. 
thyroglobulin (Mr 660000) and the void volume, 
indicating a relatively large M, complex. When 
preincubation of platelets with 2-nitro[3H]imipra- 
mine was carried out in the presence of 10 ,xM 
unlabelled imipramine, the radioactivity of this 
peak was dramatically diminished while the radio- 
activity of the second peak remained unchanged 
(fig. 3) 
4. DISCUSSION 
An estimation of the molecular size of the deter- This study reports the successful solubilization 
gent-solubilized binding site was obtained by gel of high affinity [3H]imipramine binding sites from 
filtration chromatography of the receptor- human platelets. The solubilized binding sites have 
ligand complex using a calibrated Sepharose virtually identical properties and characteristics of 
CL-6B column. Fig. 3 shows the elution profile of 
the solubilized fraction obtained from 2-nitro[3H]- 
the membrane-bound binding sites. Specific bin- 
ding in the solubilized preparation is of high affi- 
imipramine preincubated platelets. The bulk of nity with an app. & which is identical to that 
bound 2-nitro[3H]imipramine radioactivity, which found in intact platelet membranes [4]. Further- 
was sensitive to displacement by an excess of more, the pharmacological profile of the solubiliz- 
unlabelled imipramine (lOrM), migrated in a posi- ed binding site is also very similar to that of the 
tion betweeen that of the marker protein membrane-bound binding site. The sodium 
Table 1 
Effects of drugs on specific [3H]imipramine binding to 
solubilized and membrane-bound binding sites 
VCSO (nM)l 
Compound Solubilized Membrane- 
bound 
Imipramine 
Chlorimipramine 
Amitriptyline 
2-Hydroxy- 
imipramine 
Norzimelidine 
Nortriptyline 
Desipramine 
Zimelidine 
Atropine 
Phentolamine 
I 
10 
15 44 
21 64 
70 74 
120 130 
7000 1500 
> 10000 > 10000 
> 10000 > 10000 
3 
2 
17 
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Fig. 3. Sepharose CLdB gel filtration chromatography of the CHAPS-solubilized extract of 2-nitro[3H]imipramine-pre- 
incubated platelet membranes: 2ml of the 0.5% CHAPS extract was applied to Sepharose CLdB column and eluted 
at 0°C with O.OSYo CHAPS in buffer A as described in section 2. Platelet membranes were preincubated with 2nM 
2-nitro[3H]imipramine with (0) or without (0) 1OpM unlabelled imipramine, prior to the solubilization. Protein con- 
centrations (A) were measured as in [13]. V, is the void volume, and elution volumes for thyroglobulin (TG), ferritin 
(Fer) and catalase (Ct) are shown. The figure represents a typical elution profile of 3 separate exp. 
dependency of [3H]imipramine binding to both the 
soluble and membrane-bound sites [5] suggests 
that the sodium recognition or regulatory site 
associated with the high affinity [3H]imipramine 
binding site is retained in an active form during 
solubilization. These data suggest hat many (if not 
all) of the properties of this binding site are 
unaltered during solubilization and that the 
detergent CHAPS is capable of substituting for the 
membrane lipids in maintaining the active confor- 
mation of the site. Since the binding is very sen- 
sitive to both heat and proteolytic enzyme(s) it is 
likely that a protein is a major constituent of the 
[3H]imipramine binding site. The size of this pro- 
tein, estimated by gel filtration chromatography, is 
>M, 700 000. However, detergent molecules, 
lipids, and associated proteins, other than the im- 
ipramine binding site, may contribute to the large 
size of this species. 
Using digitonin as detergent and a flow-dialysis 
method for measuring [3H]imipramine binding, 
solubilization of the serotonin ‘transporter’ from 
porcine platelets was reported [14]. It is unclear 
however, if the solubilized site reported here is 
identical to the site reported by these investigators 
since there is a large difference in the affinities of 
[3H]imipramine for the two sites. Here, we observ- 
ed very high affinity binding to the solubilized site 
with an app. Kd = (1.2 nM) which is identical to the 
apparent dissociation constant of the membrane- 
bound site. In contrast, [14] reported the apparent 
affinity of [3H]imipramine for the solubilized site 
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to be almost 40-times lower (& = 45 nM). This 
discrepency may also relate to a species difference 
between porcine and human platelet membranes. 
Nevertheless, in human platelets we have observed 
a much more efficient solubilization of [3H]im- 
ipramine binding sites with CHAPS, as compared 
to digitonin (unpublished). Reconstitution of the 
solubilized sites into liposomes followed by 
measuring both [3H]imipramine binding and 
[‘Hlserotonin uptake in the reconstituted organeles 
is important in understanding the molecular com- 
ponents of the serotonin transporter complex. 
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